Streetbeat News

Revenues

ANDE

Andersons (NASDAQ:ANDE) reported Q4 2023 adjusted EPS of $1.59, surpassing the $0.99 estimate by 60.61%, but its sales of $3.21B fell short of the $4.26B estimate by 24.63%, marking a 31.30% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:11 pm

MFIN

Medallion Financial Corp. (MFIN) reported Q4 2023 earnings of $0.60 per share, missing the consensus estimate of $0.63 by 4.76%. However, their quarterly sales of $52.01M exceeded the $49.89M estimate by 4.24%, marking a 16.98% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:07 pm

TDOC

Teladoc Health (TDOC) reported Q4 sales of $660.5M, missing the consensus estimate of $671.43M by 1.63%. This represents a 3.57% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:05 pm

VMC

Vulcan Materials (NYSE:VMC) has received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for VMC has been raised to $260.57, indicating a 5.64% increase from the previous target. Analysts from firms like RBC Capital, Goldman Sachs, and Morgan Stanley have adjusted their ratings and price targets, reflecting evolving market conditions and Vulcan Materials' performance. Despite challenges in revenue growth and financial metrics such as ROE and ROA, Vulcan Materials remains the largest U.S. producer of construction aggregates.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 8:01 pm

MSFT

Microsoft's Xbox Game Pass has reached 34 million subscribers, a 36% increase from the last reported figure two years ago. The service will add seven new titles by the end of February and beginning of March 2024, including notable games like Diablo IV and Madden NFL 24. This growth reflects the expanding appeal of the Game Pass, although Microsoft emphasizes that their goal is not to make everyone a subscriber.

Portfolio Pulse from Franca Quarneti

February 20, 2024 | 7:28 pm

JCI

Analyst evaluations of Johnson Controls Intl (JCI) over the last three months show diverse opinions, with a total of 12 ratings ranging from bullish to bearish. The average 12-month price target for JCI is now $58.33, down 0.93% from the previous $58.88. Analyst actions include adjustments to ratings and price targets, reflecting responses to market conditions and company performance. JCI's financial performance indicates a positive revenue trend with a growth rate of 0.43% as of December 31, 2023, but its net margin, ROE, and ROA are below industry averages, suggesting challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 7:01 pm

PBF

Four financial analysts have recently updated their ratings and price targets on PBF Energy (NYSE:PBF), showing a mix of bullish, somewhat bullish, and indifferent stances. The average 12-month price target is now $51.25, down from $57.67, indicating a negative sentiment shift. Analysts from JP Morgan, Piper Sandler, Mizuho, and UBS have adjusted their ratings and targets, reflecting changes in market conditions and PBF Energy's performance. Despite facing revenue challenges and below-average profitability metrics, PBF Energy's market position remains robust due to its significant market capitalization and balanced debt approach.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 7:01 pm

NVO

In the last three months, 7 analysts have rated Novo Nordisk (NVO) as somewhat bullish, with recent ratings showing a positive trend. The average 12-month price target for NVO is now $130.71, marking a 16.19% increase from the previous target of $112.50. Novo Nordisk, a leader in diabetes care, has shown strong financial performance with a revenue growth of 36.95%, a net margin of 33.35%, and an ROE of 22.01%. Analysts' actions and price target adjustments reflect their optimistic outlook on the company's future performance.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 7:01 pm

CTLT

Recent analysis of Catalent (NYSE:CTLT) by 5 analysts over the past three months shows a unanimous indifferent stance with no change in sentiment in the last 30 days. The 12-month price target for CTLT has been adjusted to an average of $60.2, marking a 12.17% increase from the previous target of $53.67. Despite this optimistic adjustment in price targets, Catalent's financial health indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management suggest potential challenges ahead. The company's reliance on borrowed funds and below-average profitability and efficiency metrics could impact its stock performance.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 7:00 pm

BNTX

BioNTech (NASDAQ:BNTX) has received mixed analyst ratings over the last three months, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for BNTX has been adjusted to $127.5, down from $135.67, reflecting a 6.02% decrease. Analysts from Canaccord Genuity, HC Wainwright & Co., and JP Morgan have updated their ratings and price targets, indicating varied expectations for the company's performance. BioNTech, known for its COVID-19 vaccine Comirnaty and cancer therapeutics, faces challenges in revenue growth and profitability, with a significant revenue decline of -74.13% over the past three months.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 7:00 pm